arrow
G

Gustavo Werutsky

latin american cooperative oncology group
H指数:27
被引数:3,976

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Independent cancer research in low- and middle-income countries: why it matters and how to build it

低收入和中等收入国家的独立癌症研究:为何重要及如何构建

2026-09-070
OAAI
Pre-Analytical and Analytical Challenges in Whole-Exome Sequencing of Formalin-Fixed Paraffin-Embedded Breast and Prostate Cancer Tissue: A Real-World Multicenter Study

甲醛固定石蜡包埋乳腺癌和前列腺癌组织全外显子测序的预分析及分析挑战:一项真实世界多中心研究

2026-05-230
OA
Author Correction: Advancing equitable access to innovation in breast cancer

作者更正:促进乳腺癌创新成果的公平获取

2025-12-160
OAAI
Corrigendum to “Climate change impacts and sustainability integration among breast international group members” [The Breast Volume 81 June 2025 104469]

勘误: “Climate change impacts and sustainability integration among breast international group members” [The Breast Volume 81 June 2025 104469]

2025-11-180
OAAI
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

新辅助系统性乳腺癌治疗试验中局部区域治疗报告的核心结局指标集

2025-10-280
OA
Factors associated with accepting chemotherapy despite the risk of fertility loss in Latin American breast cancer patients—LACOG 0414 study

与拉美乳腺癌患者尽管存在生育力丧失风险仍接受化疗相关的因素—LACOG 0414研究

2025-10-020
OA
Advancing equitable access to innovation in breast cancer

促进乳腺癌创新的公平获取

2025-07-100
OAAI
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution

GOG基金会和EVA/LACOG合作伙伴关系:一个用于临床 trial 执行的协作战略联盟

2025-06-270
PRE
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

风险降低手术与年轻BRCA携带者乳腺癌患者生存期的关联:一项国际队列研究

2025-05-080
PRE
Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country
2025-03-010
OA
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2-breast cancer

TROPION-Breast04:一项针对治疗初治早期三阴性或HR低表达/HER2阳性乳腺癌患者的新辅助达托妥单抗德鲁替康(Dato-DXd)联合度伐利尤单抗,随后进行辅助度伐利尤单抗与标准护理对照的随机III期研究

2025-02-051
OA
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
2025-01-230
OAAI
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer

雄激素受体通路抑制剂疗法用于晚期前列腺癌

2025-01-132
OA
Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review☆
EJSO
IF2.9
2024-10-010
PRE
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma
2024-06-030
OAAI
Clinicopathological Characteristics and Factors Associated With Screening and Late-Stage Diagnosis in Patients With Breast Cancer in Latin America: The LATINA Study (LACOG 0615/MO39485)
2024-05-020
PRE
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
The Impact of Socioeconomic Factors on Breast Cancer Diagnosis in Latin America: The LATINA study (LACOG 0615/MO39485)
2024-05-020
PRE